Results 81 to 90 of about 188,223 (344)
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective We aimed to investigate the comparative effectiveness of standard versus personalized extended interval dosing of anti‐CD20 therapy on clinical and sub‐clinical outcomes in multiple sclerosis. Methods Clinical information was collected prospectively on Research Electronic Data Capture.
Nabil K. El Ayoubi +6 more
wiley +1 more source
Brain abscess following rituximab infusion in a patient with pemphigus vulgaris. [PDF]
, 2015 BackgroundImmunocompromised patients are at increased risk for developing meningitis or, rarely, brain abscess with opportunistic organisms like Listeria monocytogenes.Case reportA 52 year-old Saudi Arabian woman who was diagnosed with pemphigus vulgaris
Al-Harbi, Talal M +2 more
core +2 more sources
Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus--report of 17 cases and review of the literature [PDF]
, 2013 Cutaneous manifestations occur frequently in systemic lupus erythematosus (SLE) and are pathognomonic in subacute-cutaneous lupus erythematosus (SCLE) and chronic cutaneous lupus erythematosus (CCLE).
Hofmann, SC +3 more
core +1 more source
Arthritis Care &Research, EarlyView.Objective Autoimmune rheumatic diseases commonly affect individuals of childbearing age, with historically increased adverse pregnancy outcomes in this group. The advent of disease‐modifying antirheumatic drugs (DMARDs) has fostered more suitable conditions for pregnancy; however, this is accompanied by challenges in ensuring safe use in reproductive ...
Athena Chin +4 more
wiley +1 more source
Response to rituximab in children and adults with immune thrombocytopenia (ITP)
Research and Practice in Thrombosis and Haemostasis, 2021 Background Rituximab is a monoclonal anti‐CD20 antibody used as a second‐line treatment for immune thrombocytopenia (ITP). As additional treatments for ITP emerge, identifying the most appropriate patients and optimal timing for rituximab are important ...
Emily M. Harris +4 more
doaj +1 more source
B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis. [PDF]
, 2009 The approach to treating autoimmune disorders is currently undergoing a significant change in focus. As therapies are developed that are more precise in targeting the pathogenesis for these diseases, patients experience significantly fewer side effects ...
Sands, Jacob, Tuscano, Joseph M
core +2 more sources
Selection of DNA nanoparticles with preferential binding to aggregated protein target. [PDF]
, 2016 High affinity and specificity are considered essential for affinity reagents and molecularly-targeted therapeutics, such as monoclonal antibodies.
De Maere, Elisabeth +10 more
core +1 more source
Advanced Science, EarlyView.Sympathetic nerve innervation promotes the progression of Epstein‐Barr virus‐positive diffuse large B‐cell lymphoma (EBV+ DLBCL) via β2‐adrenergic receptors. The discovery of enhanced nerve infiltration and β2AR expression reveals a novel mechanism and highlights the sympathetic–β2AR axis as a promising target for therapeutic intervention in EBV+ DLBCL.
Silan Huang +10 more
wiley +1 more source
A Case of Primary Biliary Cirrhosis That Progressed Rapidly after Treatment Involving Rituximab
Case Reports in Gastroenterology, 2013 Primary biliary cirrhosis (PBC) is a progressive liver disease for which limited therapies are recommended. Rituximab, an anti-CD20 monoclonal antibody, is expected to be a useful therapeutic regimen for PBC.
Kazuto Tajiri +5 more
doaj +1 more source
CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies [PDF]
, 2016 Expression of CD20 antigen by the most of transformed B cells is believed to be the driving force for targeting this molecule by using anti-CD20 monoclonal antibodies. While it is true that most lymphoma/leukemia patients can be cured, these regimens are
Ahmadzadeh, V. +2 more
core +1 more source